표적 돌연변이 IDH1 억제제인 올루타시데닙과 병용한 데시타빈 및 베네토클락스에 대한 1b/2상 연구
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Primary Objectives
- Phase 1b: To determine the safety and tolerability and recommended phase 2 dose (RP2D) of decitabine (either IV or oral decitabine/cedazuridine (ASTX727, Inqovi)) and venetoclax in combination with olutasidenib.
- Phase 2: To determine the composite remission rate (CR, CRh and CRi) of decitabine (IV or oral decitabine/cedazuridine (ASTX727, Inqovi)) and venetoclax in combination with olutasidenib for newly diagnosed (Arm A) or relapsed/refractory (Arm B) participants with IDH1-mutated myeloid malignancy.
Secondary Objectives
- To determine duration of response (DOR), event-free survival (EFS), and overall survival (OS)
- To evaluate occurrence of minimal residual disease (MRD) negative status by multiparameter flow cytometry and molecular evaluation.
- To determine the overall response rate (CR, CRh, CRi, MLFS, and PR)
- To characterize the pharmacokinetic (PK) profiles of venetoclax and olutasidenib in plasma samples (Phase 1b only).
Exploratory Objectives
- To investigate global gene expression profiles, DNA methylation profiles, BH3 profiling and other potential prognostic markers to explore predictors of antitumor activity and/or resistance to treatment.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Courtney DiNardo, MD
- 전화번호: (713) 794-1141
- 이메일: cdinardo@mdanderson.org
연구 장소
-
-
Florida
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami
-
수석 연구원:
- Justin Watts, MD
-
연락하다:
- Justin Watts, MD
- 전화번호: 305-243-8986
- 이메일: jxw401@med.miami.edu
-
-
Kansas
-
Westwood, Kansas, 미국, 66205
- 모병
- The University of Kansas Medical Center
-
연락하다:
- Yacoub Abdulraheem, MD
- 이메일: ayacoub@kumc.edu
-
수석 연구원:
- Yacoub Abdulraheem, MD
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana-Farber Cancer Institute
-
수석 연구원:
- Jacqueline Garcia, MD
-
연락하다:
- Jacqueline Garcia, MD
- 전화번호: 617-632-6349
- 이메일: jacqueline_garcia@dfci.harvard.edu
-
-
New York
-
Buffalo, New York, 미국, 14263
- 모병
- Roswell Park
-
수석 연구원:
- Eunice Wang, MD
-
연락하다:
- Eunice Wang, MD
- 이메일: eunice.wang@roswellpark.org
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- MD Anderson Cancer Center
-
연락하다:
- Courtney DiNardo, MD
- 전화번호: 713-794-1141
- 이메일: cdinardo@mdanderson.org
-
수석 연구원:
- Courtney DiNardo, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Age > 18 years
-
Participants must have a documented IDH1 gene mutation
-
Participants with a diagnosis of relapsed or refractory AML (including biphenotypic or bilineage leukemia including a myeloid component or isolated extramedullary AML), high-risk MDS by IPSS-R or IPSS-M; OR
-
Participants with newly diagnosed AML not eligible or appropriate for intensive chemotherapy are also eligible. (Phase 2 portion only)
-
To be considered not eligible for intensive chemotherapy, participants must be defined by the following: Age 75 years or older, or Age 18 to 74 years with at least one of the following comorbidities:
- Severe cardiac disorder (eg, congestive heart failure requiring treatment, ejection fraction ≤50%, or chronic stable angina).
- Severe pulmonary disorder (eg, DLCO ≤65% or forced expiratory volume in 1 second [FEV1] ≤65%).
- Creatinine clearance ≥30 mL/min to <45 mL/min.
- Moderate hepatic impairment with total bilirubin >1.5 to .3.0 x upper limit of normal (ULN)
- ECOG performance status of 2 or 3
- Any other comorbidity that per the investigator renders a patient inappropriate for intensive chemotherapy
-
Eastern Cooperative Oncology Group (ECOG) Performance Status </=2 (unless age 18 to 74 years of age with newly diagnosed AML not eligible for intensive chemotherapy as per 5e above)
-
Adequate renal function including creatinine < 1.5, unless related to the disease or unless age 18 to 74 years of age with newly diagnosed AML not eligible for intensive chemotherapy as per 5c above.
-
Adequate hepatic function (direct bilirubin < 2x upper limit of normal (ULN) unless increase is due to Gilbert fs disease or leukemic involvement, and AST and/or ALT < 3x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5x ULN will be considered eligible, or unless age 18 to 74 years of age with newly diagnosed AML not eligible for intensive chemotherapy as per 5d above)
-
In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 14 days for cytotoxic or non-cytotoxic (immunotherapy agent(s), or an interval of 5 half-lives of the prior therapy. Oral hydroxyurea and/or cytarabine (up to 2 g/m2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the PI. Concurrent intrathecal therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted.
-
Male participants who are sexually active with a women of childbearing potential (WOCBP) and who have not had vasectomies must be willing to use a barrier method of contraception and refrain from sperm donation from initial study drug until 90 days after last dose of study drug.
-
Willing and able to provide informed consent.
Exclusion Criteria:
- Participants with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML).
- Participants with any concurrent uncontrolled clinically significant medical condition including life-threatening severe infection, or psychiatric illness, which could place the participants at unacceptable risk of study treatment.
- Participants with active, uncontrolled leukemia involvement of the CNS
- Participants with active graft-versus-host-disease (GVHD) status post stem cell transplant including active cGVHD requiring topic therapy. Patients must have discontinued calcineurin inhibitors at least 4 weeks prior to start of study treatment.
- Participants with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications.
- Known active hepatitis B (HBV) or Hepatitis C (HCV) infection or known HIV infection.
- Participant has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea and cytarabine is permitted to meet this criterion.)
- Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception.
A) Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, IUD, and double barrier methods (for example a condom in combination with a spermicide).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Part 1
Participants enrolled in Part 1, the dose of venetoclax/decitabine you receive will depend on when you join this study. Up to 3 dose levels will be tested. Up to 6 participants will be enrolled at each dose level. - All participants will receive the same dose level of olutasidenib. |
Given by PO
다른 이름들:
Given by IV
다른 이름들:
Given by PO Given by PO
다른 이름들:
|
|
실험적: Part 2
Participants enrolled in Part 2, you will receive venetoclax/decitabine at the recommended dose that was found in Part 1. - All participants will receive the same dose level of olutasidenib. |
Given by PO
다른 이름들:
Given by IV
다른 이름들:
Given by PO Given by PO
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety and adverse events (AEs)
기간: Through study completion; an average of 1 year.
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Through study completion; an average of 1 year.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Courtney DiNardo, MD, M.D. Anderson Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2024-0180
- NCI-2024-04807 (기타 식별자: NCI-CTRP Clinical Registry)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .